Acta Oncol. 1997;36:517–25.PubMedCrossRef 20. Smythies JR. Letter: nicotinamide treatment of schizophrenia. Lancet. 1973;2:1450–1.PubMedCrossRef 21. Pozzilli P, Browne PD, Kolb H. PRI-724 in vitro Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care. 1996;19:1357–63.PubMedCrossRef 22. Karpe F, Frayn KN. The nicotinic acid receptor—a new mechanism for an old drug. Lancet. 2004;363:1892–4.PubMedCrossRef 23. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415–20.PubMedCrossRef Selleckchem MRT67307 24. Kamanna VS, Kashyap ML. Mechanism

of action of niacin. Am J Cardiol. 2008;101:S20–6.CrossRef 25. Sampathkumar K. Niacin and analogs for phosphate control in dialysis–perspective from a developing country. Int Urol Nephrol. 2009;41:913–8.PubMedCrossRef 26. Kirkland JB. Niacin status impacts chromatin structure. J Nutr. 2009;139:2397–401.PubMedCrossRef 27. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008;153(Suppl 1):S68–75.PubMed 28. Berndt TJ, Pfeifer JD, Knox FG, Kempson SA, Dousa TP. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate SB-715992 deprivation. Am J Physiol. 1982;242:F447–52.PubMed 29. Kempson SA,

Colon-Otero G, Ou SY, Turner ST, Dousa TP. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest. 1981;67:1347–60.PubMedCrossRef 30. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant. 2005;20:1378–84.PubMedCrossRef Selleckchem Fludarabine 31. Katai

K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant. 1999;14:1195–201.PubMedCrossRef 32. Sabbagh Y, O’Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol. 2009;20:2348–58.PubMedCrossRef 33. Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012;23:1691–700.PubMedCrossRef 34. Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes. 1995;44:152–5.PubMedCrossRef 35. Stratford MR, Dennis MF, Hoskin P, Phillips H, Hodgkiss RJ, Rojas A. Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Br J Cancer. 1996;74:16–21.PubMedCrossRef 36. Dragovic J, Kim SH, Brown SL, Kim JH. Nicotinamide pharmacokinetics in patients. Radiother Oncol. 1995;36:225–8.